National and Kapodistrian University of Athens
Ανάπτυξη in-vitro φαρμακοκινητικού/φαρμακοδυναμικού μοντέλου για την μελέτη της δράσης αντιμυκητιακών φαρμάκων και των συνδυασμών τους έναντι ειδών ασπεργίλλου
Abstract
dc:descriptionINTRODUCTION. The in vitro activities of antifungal agents against Aspergillus spp. are determinedby standardized broth microdilution assays where the drug concentration remains constantover time (Cantón et al, 2009). However, fungi are exposed in vivo to fluctuating drugconcentrations over time because of absorption, elimination, excretion, metabolism, anddistribution processes (Groll et al, 1998). The purposes of this study were to develop an invitro model that simulates the pharmacokinetics of amphotericin B, voriconazole, andcaspofungin in humans after the intravenous administration of standard doses and tostudy the effects of standard dosing regimes and explore alternative single andcombination dosing regimens against clinical isolates of A. fumigatus, A. flavus, and A.terreus.MATERIALS AND METHODS. Three isolates of A. fumigatus, A. flavus, and A. terreus obtained from patients withinvasive pulmonary aspergillosis with amphotericin B and voriconazole CLSI MICs 1 mg/land caspofungin MECs 0.5 mg/l. The in vitro PKPD simulation model consisted of a 10-mlvolumedialysis tube (internal compartment IC) made of a semipermeable cellulosemembrane (Float-A-Lyzer; Spectrum Europe B.V., Breda, The Netherlands) allowing thefree diffusion of small molecules (MW=20 kDa). This is placed in a glass beaker containing700 ml medium (external compartment EC) the content of which is continuously diluted bya peristaltic pump (Minipuls Evolution; Gilson Inc., Villiers le Bel, France) removing drugcontainingmedium from the EC and adding drug-free medium to the EC at a rateequivalent to drug clearance in human plasma. At time zero, the IC was inoculated with 10ml medium containing 1x105CFU/ml of Aspergillus conidia. The following doses ofantifungal agents were simulated in the in vitro model: 0.25, 0.5, 1, 2 mg/kg foramphotericin B, 0.5, 1, 1.5 mg/kg for caspofungin, and 3, 4, 5 mg/kg for voriconazole.The GIs in the IC were measured at regular time intervals up to 72 h. Finally, twelvedifferent combinations of amphotericin B and voriconazole were investigated against A.fumigatus. The IC was inoculated with a conidial suspension (103CFU/mL), while drug combinations were injected in both compartments (VOR/12h, AMB/24h). The PD analysisfor the interactions studied was described using the Bliss independence model.RESULTS. Pharmacokinetic analysis. A) Voriconazole. The one compartmentpharmacokinetic model described well the drug levels in the IC (R2>0.97). Intra-and interexperimentalvariation of the in vitro PK data was <10 %. In vitro voriconazolepharmacokinetics were close to the target values observed in human plasma afteradministration of 3, 4 and 5 mg/kg voriconazole with t1/2 5.7-6.5h. b) Amphotericin B.The Cmax and AUCs in the IC for the simulated amphotericin B doses 0.25, 0.5, 1 and 1.5mg/kg were close ot those observed in humans respectively with t1/2,α 0.2-2h, t1/2,β 10-17h and t1/2,γ 71h. c) Caspofungin. In vitro caspofungin pharmacokinetics was closed tothe target values observed in human plasma after administration of 0.5, 1 and 2 mg/kgcaspofungin with t1/2 of 14.8-11.6h as in patients’ plasma.Pharmacodynamic analysis. a) Voriconazole. All three voriconazole dosesdelayed galactomannan production by A. fumigatus whereas only the two highest dosesdecreased the maximum galactomannan production compared to growth control. In thecase of A. flavus, there was no delay in galactomannan production, whereas maximumgalactomannan production was reduced as voriconazole dose increased. Regarding A.terreus, voriconazole delayed galactomannan production whereas maximumgalactomannan production was reduced as voriconazole dose increased. Based on thenormalized PKPD relationship, the fAUC0-24 associated with near-maximum activity (10%AUCGI) was 18.9 (14.4-23.1) mg.h/l against A. fumigatus, 26.6 (21.1-32.9) mg.h/l againstA. flavus and 36.2 (27.8-45.7) mg.h/l against A. terreus (F2,19=17.22, p<0.0001). Theseassociated with 90% survival in an animal model of experimental aspergillosis (Mavridou,et al, 2010); thus providing a validation of the in vitro PKPD model. Bridging the in vitroPKPD data with human PK data, low median % target attainment (<45%) was found for 3mg/kg voriconazole dosing for all species. The standard dosage of 4 mg/kg was associatedwith high median % target attainment (80%) for A. fumigatus but not for A. flavus and A.terreus for which as low as 17% and 6% target attainment, respectively, was found forfAUC0-12 at the lower 95% confidence interval limit observed in patients. b)Amphotericin B. The GI–time curves were characterized by the same maximum but different rates of galactomannan production for the different amphotericin B doses andAspergillus species. Among all species and doses tested, complete inhibition ofgalactomannan production was observed only against A. fumigatus with amphotericin Bdoses corresponding to Cmax ≥2.4 mg/l whereas at lower doses, a significant delay ingalactomannan production was observed. For A. flavus, there was no complete inhibitionbut a progressive delay of galactomannan production with increasing amphotericin Bdoses. For A. terreus, the delay in galactomannan production was modest. c)Caspofungin. Caspofungin did not have any effect on galactomannan productionwhereas when Aspergillus DNA was measured by real-time PCR, 2.2-, 0.9-, and 1.6-logreductions in the CEs of A. fumigatus, A. flavus, and A. terreus, respectively, wereobserved after 6 h of incubation in the in vitro PK/PD model with (Cmax=10 mg/L) andextend to 8h with (Cmax=20 mg/L) in the presence of caspofungin compared to those ofthe drug-free controls.Combination therapy. The combination of voriconazole with amphotericin Bexerted antagonistic effects (-4 to -13%) in a wide range of doses tested with Cmax 1.7, 3.4and 7.8 mg/L for voriconazole and 0.6, 0.3 and 0.1 mg/L for amphotericin B, whereas somesynergistic interactions at a percentage of 26% were observed at lower amphotericin B andvoriconazole doses with Cmax 0.1 and 1.7 mg/L, respectively. These concentrationscorrespond to the free drug levels of amphotericin B and voriconazole achieved in humanplasma after invravenous administration of the standard doses 1 mg/kg and 4 mg/kg.DISCUSSION. Here we report for the first time, to our knowledge, a new in vitro pharmacokineticmodel for Aspergillus species that simulates the human plasma pharmacokinetics of threemajor anti-Aspergillus agents (voriconazole, amphotericin B and caspofungin). For thepharmacodynamic analysis of these regimens, galactomannan production was determinedas a surrogate marker of fungal growth. The three Aspergillus strains tested in this modelhad the same MICs and MECs and represent the most clinically significant species (A.fumigatus, A. flavus, and A. terreus). The new in vitro model revealed pharmacodynamicsdifference among the three species that were not apparent with the conventional in vitrosusceptibility testing broth microdilution methodologies where the drug concentration ofantifungal agents remained constant over time (Lewis et al, 2006). Although each isolate of the three Aspergillus species used in the present study hadthe same MIC (0.5 mg/liter), the new in vitro PK/PD model revealed significantpharmacodynamic differences, with the greatest efficacy of voriconazole found against A.fumigatus and less against A. terreus; whereas no activity against A. flavus was detected.Furthermore, the voriconazole fAUC0-24/MIC associated with near maximum activity was18.9 (14.4-23.1) mg.h/l for A. fumigatus, which is very close of the PKPD target found inin vivo experiments withy mice (Μavridou et al 2005) validating the results of the in vitromodel. Bridging these PΚPD data with human PK showed that the standard dosage of 4mg/kg was associated with a high median % target attainment for A. fumigatus (80%) butnot for A. flavus (63%) and A. terreus (36%), although a wide range of % targetattainment was observed reflecting the large inter-patient variation of voriconazole fAUC0-12. Therapeutic drug monitoring or use of higher dosages may increase the efficacy ofvoriconazole therapy for the non-fumigatus Aspergillus species.In the present study, the Aspergillus isolates exhibited the same Amphotericin BMIC (1 mg/liter), classified as susceptible (Cantón et al, 2009), suggesting similarefficacies of amphotericin B. However, the new in vitro model revealed differences in theefficacy of amphotericin B against the three Aspergillus species, with the following order:A. fumigatus > A. flavus > A. terreus. These findings are in agreement with previouscomparative animal studies where treatment with amphotericin B was more effectiveagainst infection cause by A. fumigatus than against infection with A. flavus and lesseffective against infection with A. terreus (Odds et al, 1998; Walsh et al, 2003). The newin vitro model may capture different pharmacodynamic effects beyond inhibitory actionsthat are described by the MICs such as fungicidal, time-dependenent and post-antifungaleffects.In the new in vitro model, caspofungin did not demonstrate any effect on thegalactomannan production by Aspergillus species other than A. terreus. Galactomannanmay be released during the process of cell wall disruption. Consequently, galactomannanlevels may remain high despite effective antifungal activity. Thus, for pharmacodynamicstudy of the actions of caspofungin and other echinocandins, measurement ofgalactomannan production appears not to be informative either in vitro and in vivo(Petraitiene et al, 2002). Another biomarker is needed to monitor the pharmacodynamics of echinocandins. An alternative endpoint for determining the activity of antifungal drugs,and particularly of echinocandins, may be PCR CEs.CONCUSION. In conclusion, in the present study, we developed and for the first time reported anin vitro PK/PD model which simulates the pharmacokinetics of three major antifungaldrugs in humans and assesses their efficacy against three clinically significant Aspergillusspecies. In vitro PK-PD modeling voriconazole showed that higher voriconazole exposuremay be required in order to inhibit A. terreus than A. flavus and A. fumigatus. Also, thismodel simulated well amphotericin B human pharmacokinetics and demonstrated adifferential in vitro activity against the three Aspergillus species that are not reflected bythe MICs. These effects may be the sum of concentration- and time-dependentinhibitory/killing activities of amphotericin B which exhibited the greatest activity againstA. fumigatus and lowest against A. terreus. About caspofungin, it did not demonstrate anyeffect on the growth of an Aspergillus species other than A. terreus, in whichgalactomannan production was simply delayed. Consequently, galactomannan levels mayremain high despite effective antifungal activity. Thus, another biomarker is needed tomonitor the pharmacodynamics of echinocandins.Moreover, the model was applied to simulate the pharmacokinetics of antifungalcombination therapy with voriconazole and amphotericin B which is commonly used totreat refractory aspergillosis. The model showed that voriconazole interacted in aconcentration-dependent manner with amphotericin B with synergistic interactionsobserved at concentrations that corresponded to the free drugs levels obtained afterstandard dosing regimes. Thus, the voriconazole+amphotericin B combination mayenhance overall antifungal efficacy while therapeutic drug monitoring of combinationregimes may increase synergistic effects against Α. fumigatus isolates.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ai-Saigh, Rafal
Subjects
dc:subject × 16Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40933